age was 72.8 8.9 yrs, 65.1% were male and 78.7% had a history of hypertension. LTB was calculated as the proportion of patients receiving antihypertensive therapy who were not attaining guideline BP control targets. A hypothetical intervention to lower blood pressure to the normal range was applied to those individuals identified with LTB, to estimate the number of cardiovascular disease events which could be prevented. Logistic regression was used to find the predictors of LTB and event rates were compared using Chi squared tests. RESULTS: Among the 2856 Australian REACH participants, 70.1% (n 2002) had uncontrolled blood pressure ( 130/80 mmHg) and 88.3% (2522) had been taking anti-hypertensive medication. LTB was 70.7% (1784). The major univariate predictors of LTB were gender, age, diabetes, hypertension, carotid plaque, cholesterol, BMI and congestive heart failure. Assuming a hypothetical blood pressure intervention is applied to the LTB group resulting in controlled blood pressure ( 130/80 mmHg), 8 cardiac events per 1000 people and 21 cardiovascular disease events including coronary heart disease intervention per 1000 people could be prevented. CONCLUSIONS: Improving BP control in patients receiving antihypertensive medication may prevent 8 cardiac events per 1000 people and 21 CVD events per 1000 people within this study group. At a population level, this would represent a major cardiovascular event reduction strategy.
PCV84 AN ASSESSMENT OF THE COST OF PERCUTANEOUS PULMONARY VALVE IMPLANTATION USING MELODY VERSUS SURGICAL VALVE REPLACEMENT IN PATIENTS WITH RIGHT VENTRICULAR OUTFLOW TRACT DYSFUNCTION
Raikou M 1 , McGuire A 1 , Lurz P 2 , Bonhoeffer P 2 , Wegmueller Y 3 1 London School of Economics and Political Science, London, UK, 2 Great Ormond Street Hospital, London, UK, 3 Medtronic Trading Sarl, Geneva, Switzerland OBJECTIVES: To assess the cost of percutaneous pulmonary valve implantation (PPVI), a new procedure introduced in 2000 as a less invasive treatment for right a new procedure introduced in 2000 as a less invasive treatment for right ventricular outflow tract (RVOT) dysfunction, and the cost of surgical valve replaceand the cost of surgical valve replacement in patients with right ventricular outflow tract dysfunction using a cohort simulation model. METHODS: A cost analysis was performed from the perspective of the purchaser (the UK NHS). The cost of PPVI was estimated using data based on a total of 141 patients who had undergone PPVI from 2000 to 2008. The cost of surgical valve replacement in a similar group of patients was estimated using a cohort simulation model populated with data drawn from the literature and expert opinion, given that PPVI has supplanted this procedure in the clinical setting analysed. The model is
The model is a cohort simulation model and assesses the cost of surgery using a hypothetical population of 1000 individuals with right ventricular outflow tract dysfunction starting when with right ventricular outflow tract dysfunction starting when their first valved biological conduit was surgically placed and following them for a period of 25 years assuming that 1) PPVI is not available as an option, and 2) that PPVI is available for those eligible for it. RESULTS: The model resulted in an estimate of mean cost per patient of £5276 in the absence of PPVI and in an estimate of mean cost per patient of £7958 in the presence of PPVI over the 25 years period of analysis. CONCLUSIONS: PPVI although more costly than the surgical alternative, it appears to delay surgery thus having a significant impact on the health and the quality of life of this patient population. More research is needed to quantify the magnitude of the impact on the quality of life and to assess the role of modelling generally in assessing costs and effects in medical devices. The effect of hypertension on increased risk of cardiovascular disease events has been demonstrated through population based studies, and the predictive value of SBP has been repeatedly demonstrated in risk prediction models derived from such studies. A recent meta-analysis of evidence regarding SBP reduction by ARB antihypertensives has demonstrated a significant difference in the SBP reduction observed in patients treated with valsartan, compared to those treated with losartan. An economic model has been constructed to evaluate the effect of this difference on the risk of a first CVD event, and the resulting costs. METHODS: Inputs for the model are drawn from published sources and publically available datasets. CVD risk prediction was performed using equations derived from the Framingham Offspring Study cohort. The model evaluated an untreated group, and groups treated with valsartan, and losartan. Each treatment group was stratified into those with mild hypertension or moderate hypertension. RESULTS: Basecase analyses represent outcomes over 20 years from baseline moderate HTN classification in a US population of age 18 and over. Valsartan was associated with a marginal cost of $1,983 vs. the untreated arm, and a marginal cost of $466 in comparison to losartan. These costs resulted in estimates of $33,540 per event avoided vs. untreated and $37,484 vs. losartan. Incremental costs per QALY were $7,067 vs. no treatment and $8,067 vs. losartan.
PCV85 COST CONSEQUENCES OF REDUCED CVD RISK THROUGH IMPROVED SBP CONTROL: A COMPARATIVE ANALYSIS OF VALSARTAN VERSUS LOSARTAN

CONCLUSIONS:
Analysis results indicate that reduction in SBP from baseline is associated with small reductions in primary CVD rates, and overall CVD treatment costs. Valsartan performed better than losartan because it was associated with a greater decrease in SBP from baseline (according to meta-analysis results). Overall, the calculated cost effectiveness ratios for treatment with valsartan indicate that valsartan is likely to be cost-effective when compared to no treatment or treatment with losartan in control of SBP.
PCV86 COST-EFFECTIVENESS OF TRANSCATHETER AORTIC VALVE IMPLANTATION IN HIGH-RISK PATIENTS WITH SYMPTOMATIC AORTIC VALVE STENOSIS IN FRANCE
Fagnani F 1 , Litzler PY 2 , Eltchaninoff H 2 , Cribier A 2 , Banz K 3 1 Cemka-Eval, Bourg-La-Reine, France, 2 CHU Charles Nicolle, Rouen, France, 3 Outcomes International, Basel, Switzerland OBJECTIVES: To investigate the efficiency of minimally-invasive Transcatheter Aortic Valve Implantation (TAVI) delivered through the transfemoral or transapical approach compared with open-heart conventional aortic valve replacement or medical management alone in high risk patients with aortic stenosis in France. METHODS: A longitudinal cohort model was developed to predict clinical and economic outcomes over three years in four cohorts of patients treated by either: transfemoral (TF) or transapical (TA) aortic valve implantation, surgical aortic valve replacement (AVR) or medical management (MED). Clinical outcomes included early perioperative complications (30 days) and late events (stroke, MI, endocarditis, valve reoperation, pacemaker implantation, hospitalization for acute heart failure, and death). In the absence of head-tohead clinical trials, efficacy data for the alternative approaches were extracted from various sources including clinical studies, registries, national health statistics and expert opinion. QALYs were assessed by mapping health utilities to NYHA class distribution. Direct medical costs were assessed by multiplying the number of resource items consumed with French unit costs (2008 values) . RESULTS: In terms of predicted mean life years and QALYs per patient after 3 years, TAVI appears to be superior to the other approaches; 2.42 years or 1.76 QALYs for TF, 2.16 years or 1.61 QALYs for TA, versus 2.06 years or 1.50 QALYs for AVR, and 1.73 years or 0.98 QALYs for MED. Modeled average discounted (3%) cumulative direct medical costs per patient amount to a46,677 (TF), a45,468 (TA), a50,630 (AVR), and a78,208 (MED). These findings imply that both transcatheter approaches appear to be dominant versus conventional high-risk AVR as well as medical management. Probabilistic sensitivity analyses confirmed the robustness of these model results. CONCLUSIONS: TAVI appears to be an economically promising technology. However, additional data from on-going clinical studies and registries need to be awaited to confirm these preliminary results.
